1. COPANLISIB IN COMBINATION WITH ANTI‐PD‐1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS. (June 2017) Authors: Liu, N.; Haike, K.; Glaeske, S.; Paul, J.; Mumberg, D.; Kreft, B.; Ziegelbauer, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Meat allergy associated with galactosyl‐α‐(1, 3)‐galactose (α‐Gal)—Closing diagnostic gaps by anti‐α‐Gal IgE immune profiling. Issue 1 (15th August 2017) Authors: Jappe, U.; Minge, S.; Kreft, B.; Ludwig, A.; Przybilla, B.; Walker, A.; Varga, R.; Seidel, P.; Biedermann, T.; Anemüller, W.; Kromminga, A.; Ruëff, F.; Merk, H.; Wagner, N.; Treudler, R.; Worm, M.; Waldmann, I.; Saloga, J.; Becker, W. M.; Goldmann, T. Journal: Allergy Issue: Volume 73:Issue 1(2018) Page Start: 93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Schwere Candida‐Balanoposthitis unter gleichzeitiger Therapie mit Secukinumab und dem Antidiabetikum Empagliflozin (Natrium‐Glukose‐Cotransporter 2 – SGLT2‐Inhibitor). (8th April 2019) Authors: Moldenhauer, I.; Pliquett, R.U.; Kreft, B.; Sunderkötter, C. Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 17:Number 4(2019) Page Start: 456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium‐glucose cotransporter 2 inhibitor – SGLT2‐inhibitor). (15th March 2019) Authors: Moldenhauer, I.; Pliquett, R.U.; Kreft, B.; Sunderkötter, C. Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 17:Number 4(2019) Page Start: 456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗